methemoglobinemia/tyrosine

Link salvestatakse lõikelauale

ArtiklidKliinilistes uuringutesPatendid

Valige sortimise tüüp

5 tulemused

A novel mutation in the NADH-cytochrome b5 reductase gene of a Chinese patient with recessive congenital methemoglobinemia.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Recessive congenital methemoglobinemia due to nicotinamide adenine dinucleotide (NADH)-cytochrome b5 reductase (b5R) deficiency is classified into 2 clinical types: type 1 (erythrocyte type) and type 2 (generalized type). We found a Chinese family with type 1 recessive congenital methemoglobinemia,

Hereditary methemoglobinemia caused by Hb M-Hyde Park (Hb M-Akita) (HBB:c.277C > T; p.His93Tyr).

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Healthy human blood contains only a trace amount of methemoglobin (Hb M), less than 1%. In Hb M iron is present in the oxidized ferric state (Fe³⁺) not in the reduced ferrous form (Fe²⁺) and this reduces the ability of hemoglobin to bind oxygen. The described rare hemoglobin

Congenital methemoglobinemia caused by Hb-MRatnagiri (beta-63CAT-->TAT, His-->Tyr) in an Indian family.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Hb-M is a very rare hemoglobinopathy in the Indian subcontinent. We report a family with Hb-M with lifelong cyanosis from the Ratnagiri district in western India. The propositus was a 11-year-old female child with a history of increasing cyanosis exacerbated by fever and weakness. Similar complaints

DNA sequence analysis proves Hb M-Milwaukee-2 is due to beta-globin gene codon 92 (CAC-->TAC), the presumed mutation of Hb M-Hyde Park and Hb M-Akita.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Among the causes of congenital methemoglobinemia, Hb M-Milwaukee-2 was one of the earliest described, in a patient who also had Hb E trait. The structure of Hb M-Milwaukee-2 has been elusive. DNA sequence analysis, as here reported, proves that this hemoglobin variant is due to the mutation

Blocking interaction between SHP2 and PD-1 denotes a novel opportunity for developing PD-1 inhibitors.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Small molecular PD-1 inhibitors are lacking in current immuno-oncology clinic. PD-1/PD-L1 antibody inhibitors currently approved for clinical usage block interaction between PD-L1 and PD-1 to enhance cytotoxicity of CD8⁺ cytotoxic T lymphocyte (CTL). Whether other steps along the PD-1

Liitu meie
facebooki lehega

Herbal & Natural Medicine

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus

Töötab 55 keeles
Taimsed ravimid, mida toetab teadus
Maitsetaimede äratundmine pildi järgi
Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
Lugege oma otsinguga seotud teaduspublikatsioone
Otsige ravimtaimi nende mõju järgi
Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega

Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel